| Overview |
| bs-6936R-Cy5.5 |
| MYF5 Polyclonal Antibody, Cy5.5 Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Mouse, Rat |
| Human, Cow, Sheep, Pig, Horse, Chicken, Rabbit |
| Specifications |
| Cy5.5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human MYF5 |
| 61-160/255 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 4617 |
| P13349 |
| Nucleus |
| Myf-5; bHLHc2; Class C basic helix loop helix protein 2; Class C basic helix-loop-helix protein 2; Myf 5; Myf-5; Myf5; MYF5_HUMAN; Myogenic factor 5. |
| Differentiation of myogenic cells is regulated by multiple positively and negatively acting factors. One well characterized family of helix-loop-helix (HLH) proteins known to play an important role in the regulation of muscle cell development include Myo D, myogenin, Myf-5 and Myf-6 (also designated MRF-4 or herculin). Of interest, most muscle cells express either Myo D or Myf-5 in the committed state, but when induced to differentiate, all turn on expression of myogenin. Myo D transcription factors form heterodimers with products of a more widely expressed family of bHLH genes, the E family, which consists of at least three distinct genes: E2A, IF2 and HEB. Myo D-E heterodimers bind avidly to consensus (CANNTG) E box target sites that are functionally important elements in the upstream regulatory sequences of many muscle-specific terminal differentiation genes. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz